Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor ‐ 12 months · Adults with refractive errors
1 finding from 1 review
Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment:12 months ‐ Procedure: LASIK · Adults with refractive errors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of eyes with significant visual loss (loss of 2 or more lines from pretreatment BSCVA): 12 months · Adults with refractive errors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of eyes with optical side effects, such as glare and halo: 12 months · Adults with refractive errors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment:12 months ‐ Procedure PRK · Adults with refractive errors
Wavefront procedures showed no clear difference in proportion of eyes that had lost 1 or more lines of best… compared with conventional procedures (low certainty).
1 finding from 1 review
Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months ‐ Procedure PRK · Adults with refractive errors
Wavefront procedures showed no clear difference in proportion of eyes within ± 0.50 diopters (D) of target refraction:… compared with conventional procedures (low certainty).
1 finding from 1 review
Proportion of eyes within ± 0.50 diopters (D) of target refraction: 12 months ‐ Procedure LASIK · Adults with refractive errors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of eyes that had lost 1 or more lines of best spectacle‐corrected visual acuity (BSCVA) posttreatment‐procedure LASIK; Mean higher‐order aberrations (HOAs) post‐treatment, measured by machine with wavefront sensor; proportion of eyes wi... · Adults with refractive errors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or better post‐treatment. ‐ 12 months · Adults with refractive errors
Wavefront‐optimized procedures showed no clear difference in proportion of eyes with uncorrected visual acuity (UCVA) of 20/20 or… compared with wavefront‐guided procedures (low certainty).
1 finding from 1 review
Loss of 1 or more lines of BSCVA at 12 months post treatment · Adults with refractive errors
Wavefront‐optimized procedures showed no clear difference in proportion of eyes that had lost 1 or more lines of best… compared with wavefront‐guided procedures (low certainty).
1 finding from 1 review
Cure · people who are being treated for active VL
1 finding from 1 review
Definitive cure · people who are being treated for active VL
1 finding from 1 review
Completion of treatment · people who are being treated for active VL
1 finding from 1 review
Resolution of symptoms · people who are being treated for active VL
1 finding from 1 review
Physical growth / weight gain · people who are being treated for active VL
1 finding from 1 review
Adverse outcomes · people who are being treated for active VL
1 finding from 1 review
Mortality (all‐cause) · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes mortality (All‐cause) compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Hepatorenal syndrome (Number of participants who did not achieve reversal of hepatorenal syndrome) · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes hepatorenal syndrome (Number of participants who did not achieve… compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.79 [0.63, 0.99]
394 participants
Very low
Serious adverse events · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 3.5 [1.19, 10.27]
221 participants
Very low